Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AKTX NASDAQ:BCDA NASDAQ:KZR NASDAQ:RNTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAKTXAkari Therapeutics$0.80+3.9%$0.89$0.57▼$3.15$26.09M0.36314,878 shs115,160 shsBCDABioCardia$1.45$1.69$1.00▼$3.20$8.42M0.8635,878 shs83,443 shsKZRKezar Life Sciences$6.36+52.5%$4.00$3.53▼$8.45$46.57M0.62137,723 shs5.93 million shsRNTXRein Therapeutics$1.22-4.7%$1.22$1.04▼$4.40$28.43M1.14215,806 shs84,779 shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAKTXAkari Therapeutics+3.88%-13.99%+0.79%-29.21%-68.26%BCDABioCardia0.00%+8.21%-5.54%-34.98%-44.97%KZRKezar Life Sciences+52.52%+50.71%+70.05%+46.21%-28.91%RNTXRein Therapeutics-4.69%-6.15%+6.09%-14.08%+121,999,900.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAKTXAkari Therapeutics$0.80+3.9%$0.89$0.57▼$3.15$26.09M0.36314,878 shs115,160 shsBCDABioCardia$1.45$1.69$1.00▼$3.20$8.42M0.8635,878 shs83,443 shsKZRKezar Life Sciences$6.36+52.5%$4.00$3.53▼$8.45$46.57M0.62137,723 shs5.93 million shsRNTXRein Therapeutics$1.22-4.7%$1.22$1.04▼$4.40$28.43M1.14215,806 shs84,779 shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAKTXAkari Therapeutics+3.88%-13.99%+0.79%-29.21%-68.26%BCDABioCardia0.00%+8.21%-5.54%-34.98%-44.97%KZRKezar Life Sciences+52.52%+50.71%+70.05%+46.21%-28.91%RNTXRein Therapeutics-4.69%-6.15%+6.09%-14.08%+121,999,900.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAKTXAkari Therapeutics 2.33Hold$3.30312.55% UpsideBCDABioCardia 2.50Moderate Buy$25.001,624.14% UpsideKZRKezar Life Sciences 1.67Reduce$6.00-5.66% DownsideRNTXRein Therapeutics 2.00Hold$10.00719.67% UpsideCurrent Analyst Ratings BreakdownLatest BCDA, KZR, AKTX, and RNTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/17/2025KZRKezar Life SciencesWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetEqual Weight$7.00 ➝ $5.0010/17/2025KZRKezar Life SciencesJefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Hold$18.00 ➝ $7.0010/17/2025KZRKezar Life SciencesTD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Strong Sell10/17/2025KZRKezar Life SciencesWilliam BlairSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform ➝ Market Perform10/8/2025AKTXAkari TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/8/2025BCDABioCardiaWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/8/2025KZRKezar Life SciencesWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/8/2025RNTXRein TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025AKTXAkari TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025BCDABioCardiaWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025KZRKezar Life SciencesWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)(Data available from 10/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAKTXAkari TherapeuticsN/AN/AN/AN/A$0.84 per shareN/ABCDABioCardia$60K140.41N/AN/A$0.18 per share8.06KZRKezar Life Sciences$7M6.65N/AN/A$16.02 per share0.40RNTXRein TherapeuticsN/AN/A$0.45 per share2.73$0.43 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAKTXAkari Therapeutics-$19.79MN/A0.00∞N/AN/A-78.03%-31.62%11/18/2025 (Estimated)BCDABioCardia-$7.95M-$1.85N/AN/AN/AN/A-19,117.42%-246.92%11/12/2025 (Estimated)KZRKezar Life Sciences-$83.74M-$9.69N/AN/AN/AN/A-63.51%-52.13%11/11/2025 (Estimated)RNTXRein Therapeutics-$62.88M-$2.69N/AN/AN/AN/A-141.11%-33.83%N/ALatest BCDA, KZR, AKTX, and RNTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/12/2025Q3 2025BCDABioCardia-$0.25N/AN/AN/AN/AN/A11/11/2025Q3 2025KZRKezar Life Sciences-$1.81N/AN/AN/AN/AN/A8/14/2025Q2 2025RNTXRein Therapeutics-$0.22-$0.28-$0.06-$0.28N/AN/A8/13/2025Q2 2025KZRKezar Life Sciences-$2.15-$1.87+$0.28-$1.87N/AN/A8/11/2025Q2 2025BCDABioCardia-$0.50-$0.40+$0.10-$0.40N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAKTXAkari TherapeuticsN/AN/AN/AN/AN/ABCDABioCardiaN/AN/AN/AN/AN/AKZRKezar Life SciencesN/AN/AN/AN/AN/ARNTXRein TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAKTXAkari TherapeuticsN/A0.190.19BCDABioCardiaN/A0.330.33KZRKezar Life Sciences0.037.297.29RNTXRein TherapeuticsN/A0.860.86Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAKTXAkari Therapeutics5.06%BCDABioCardia20.57%KZRKezar Life Sciences67.90%RNTXRein Therapeutics90.89%Insider OwnershipCompanyInsider OwnershipAKTXAkari Therapeutics38.10%BCDABioCardia20.00%KZRKezar Life Sciences10.40%RNTXRein Therapeutics5.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAKTXAkari Therapeutics932.62 million20.19 millionNot OptionableBCDABioCardia405.81 million4.65 millionOptionableKZRKezar Life Sciences607.32 million6.56 millionNot OptionableRNTXRein Therapeutics923.31 million22.12 millionN/ABCDA, KZR, AKTX, and RNTX HeadlinesRecent News About These CompaniesRein Therapeutics Receives European Regulatory Approval to Initiate Phase 2 Trial of LTI-03 in Idiopathic Pulmonary FibrosisOctober 9, 2025 | globenewswire.comRein Therapeutics (RNTX) Price Target Increased by 42.86% to 10.20October 1, 2025 | msn.comHC Wainwright & Co. Initiates Coverage of Rein Therapeutics (RNTX) with Buy RecommendationSeptember 22, 2025 | msn.comRein Therapeutics initiated with a Buy at H.C. WainwrightSeptember 22, 2025 | msn.comRein Therapeutics announces publication of data on LTI-03 in IPFSeptember 17, 2025 | msn.comRein Therapeutics Announces Publication of New Translational Data in iScience on Company’s Novel Therapy for Idiopathic Pulmonary FibrosisSeptember 17, 2025 | markets.businessinsider.comRein Therapeutics Announces Publication of New Translational Data in iScience on Company's Novel Therapy for Idiopathic Pulmonary FibrosisSeptember 17, 2025 | globenewswire.comRein Therapeutics files to sell 10M shares of common stock for holdersSeptember 3, 2025 | msn.comBrookline Capital Downgrades Rein Therapeutics (RNTX)August 19, 2025 | msn.comRein announces U.K. MHRA authorized to initiate Phase 2 ‘RENEW’ trialAugust 19, 2025 | msn.comRein Therapeutics Wins U.K. Approval to Launch Phase 2 Clinical Trial of LTI-03 in Idiopathic Pulmonary FibrosisAugust 19, 2025 | globenewswire.comRein Therapeutics to Present Novel IPF Science and Clinical Development Insights at IPF Summit 2025August 14, 2025 | globenewswire.comXtalPi and DoveTree Announce Landmark $6 Billion AI Drug Discovery CollaborationAugust 7, 2025 | finance.yahoo.comRein Therapeutics Enters into Agreements for up to $21 Million in Flexible FinancingJuly 30, 2025 | finance.yahoo.comRNTX - Rein Therapeutics Inc Dividends - MorningstarJune 26, 2025 | morningstar.comMRein Therapeutics Announces Adjournment of Annual Meeting of StockholdersJune 24, 2025 | prnewswire.comUS FDA puts on hold Rein Therapeutics' lung disease drug trialJune 12, 2025 | reuters.comRNTX Rein Therapeutics Inc.June 1, 2025 | seekingalpha.comRein Therapeutics, Inc.: Rein Therapeutics Announces First Patient Dosed in RENEW Phase 2 Trial of LTI-03 in Patients with IPFMay 27, 2025 | finanznachrichten.deRein Therapeutics Announces First Patient Dosed in RENEW Phase 2 Trial of LTI-03 in Patients with IPFMay 27, 2025 | prnewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeBCDA, KZR, AKTX, and RNTX Company DescriptionsAkari Therapeutics NASDAQ:AKTX$0.80 +0.03 (+3.88%) Closing price 10/17/2025 04:00 PM EasternExtended Trading$0.80 0.00 (-0.11%) As of 10/17/2025 05:18 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration. The company is based in London, the United Kingdom.BioCardia NASDAQ:BCDA$1.45 0.00 (0.00%) Closing price 10/17/2025 03:59 PM EasternExtended Trading$1.40 -0.05 (-3.38%) As of 10/17/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia. The company is also developing an allogeneic cells therapy platform, which is an investigational culture expanded bone marrow derived mesenchymal cell therapy in Phase I/II trial to treat ischemic heart failure and acute respiratory distress syndrome. In addition, it offers the Helix biotherapeutic delivery system for minimally invasive targeted delivery of biologic agents to the heart; and Morph deflectable guides and sheaths. The company has collaboration agreements with CellProthera in the development of ProtheraCytes, which is currently under Phase II trial for the treatment of acute myocardial infarction. BioCardia, Inc. is based in Sunnyvale, California.Kezar Life Sciences NASDAQ:KZR$6.36 +2.19 (+52.52%) Closing price 10/17/2025 04:00 PM EasternExtended Trading$6.34 -0.02 (-0.24%) As of 10/17/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of tumors resistant to traditional chemotherapeutics. Kezar Life Sciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.Rein Therapeutics NASDAQ:RNTX$1.22 -0.06 (-4.69%) As of 10/17/2025 04:00 PM EasternRein Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of a novel class of therapeutics for the treatment of cancer and other diseases. It focuses on its lead product candidate, ALRN-6924, which is a cell-permeating peptide that disrupts the interaction of p53 suppressors MDM2 and MDMX with tumor suppressor p53 to reactivate tumor suppression in non-mutant, or wild-type, p53 cancers. The company was founded by Gregory L. Verdine, Rosana Kapeller, Huw M. Nash, Joseph A. Yanchik III, and Loren David Walensky on August 6, 2001 and is headquartered in Austin, TX. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Broadcom Inks OpenAI Deal: Why It's A Huge Win for AVGO Stock Institutions Are Fueling CrowdStrike’s Next Leg Higher This AI Chip Giant Could Be the Market’s Next Big Winner Microsoft & NVIDIA Unveil GB300 Supercomputer as AI Race Heats Up This Less-Hyped Tech Stock Could Be the Key to the Next AI Wave Archer Buys Rival's Patent Treasure Trove in Strategic Move Prologis Stock Surges: Why the Rally May Continue Intel's Turnaround Hits Hyperspeed With A New 52-Week High Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
